Estimating the dose-toxicity curve in completed phase I studies

Statistics in Medicine

Volumn 30, Issue 17, 2011, Pages 2117-2129

  Iasonos, Alexia ^a   Ostrovnaya, Irina ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Constrained maximum likelihood estimation; Dose toxicity curve; Phase I trial; Retrospective continual reassessment method; Small sample size

Indexed keywords

ACCURACY; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSE CALCULATION; INTERMETHOD COMPARISON; MAXIMUM LIKELIHOOD METHOD; MAXIMUM TOLERATED DOSE; NONPARAMETRIC TEST; PLOTS AND CURVES; PROBABILITY; REGRESSION ANALYSIS; SEQUENTIAL ANALYSIS; STUDY DESIGN;

CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIKELIHOOD FUNCTIONS; MAXIMUM TOLERATED DOSE; MODELS, STATISTICAL; RETROSPECTIVE STUDIES;

EID: 79959925159     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4206     Document Type: Article

References (29)

1. Korn E, Midthune D, Chen T, Rubinstein L, Christian M, Simon R. A comparison of two phase I trial designs. Statistics in Medicine 1994; 13:1799-1806.
2. Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khuri FR, Porter A. Translation of innovative designs into phase I trials. Journal of Clinical Oncology 2007; 25:4982-4986.
3. Ahn C. An evaluation of Phase I cancer clinical trial designs. Statistics in Medicine 1998; 17:1537-1549.
4. Garrett Mayer E. The continual reassessment method for dose-finding studies: A tutorial. Clinical Trials 2006; 3:57-71.
5. He W, Liu J, Binkowitz B, Quan H. A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials. Statistics in Medicine 2006; 25:2027-2042.
6. Iasonos A, Wilton AS, Riedel ER, Seshan VE, Spriggs DR. A comprehensive comparison of the continual reassessment mehod to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clinical Trials 2008; 5:465-477.
7. Zohar S, Lian Q, Levy V, Cheung K, Ivanova A, Chevret S. Quality assessment of phase I dose-finding cancer trials: Proposal of a checklist. Clinical Trials 2008; 5:478-485.
8. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics 1990; 46:33-48.
9. Prentice RL. A generalization of the probit and logit methods for dose response curves. Biometrics 1976; 32:761-768.
10. Schmoyer RL. Sigmoidally constrained maximum likelihood estimation in quantal bioassay. Journal of the American Statistical Association 1984; 79:448-453.
11. Ivanova A, Flournoy N. Comparison of isotonic designs for dose-finding. Statistics in Biopharmaceutical Research 2009; 1:101-107.
12. Kong M, Euban RL. Monotone smoothing with application to dose-response curve. Communications in Statistics-Simulation and Computation 2006; 35:991-1004.
13. Nottingham QJ, Birch JB. A semiparametric approach to analysing dose-response data. Statistics in Medicine 2000; 19:389-404.
14. Staniswalis JG, Cooper V. Kernel estimates of dose response. Biometrics 1988; 44:1103-1119.
15. Stylianou M, Flournoy N. Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics 2002; 58:171-177.
16. Stylianou M, Proschan M, Flournoy N. Estimating the probability of toxicity at the target dose following an up-and-down design. Statistics in Medicine 2003; 22:535-543.
17. O'Quigley J. Retrospective analysis of sequential dose-finding designs. Biometrics 2005; 61:749-756.
18. O'Quigley J, Shen L. Continual reassessment method: a likelihood approach. Biometrics 1996; 52:673-684.
19. O'Quigley J, Zohar S. Experimental designs for phase I and phase I/II dose-finding studies. British Journal of Cancer 2006; 94:609-613.
20. Byrd RH, Lu P, Nocedal J, Zhu C. A limited memory algorithm for bound constrained optimization. SIAM Journal of Scientific Computing 1995; 16:1190-1208.
21. Gonen M. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in phase I trials. Controlled Clinical Trials 2005; 26:131-140.
22. Azzoli C, Krug L, Gomez J, Miller V, Kris M, Ginsberg M, Henry R, Jones J, Tyson L, Dunne M, Pizzo B, Farmer A, Venkatraman E, Steffen R, Sirotnak F. A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors. Clinical Cancer Research 2007; 13:2692-2698.
23. Kelly W, O'Connor O, Krug L, Chiao J, Heaney M, Curley T, MacGregore Cortelli B, Tong W, Secrist J, Schwartz L, Richardson S, Chu E, Olgac S, Marks P, Scher H, Richon V. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Journal of Clinical Oncology 2005; 23:3923-3931.
24. Kortmansky J, Shah M, Kaubisch A, Weyerbacher A, Yi S, Tong W, Sowers R, Gonen M, O'reilly E, Kemeny N, Ilson D, Saltz L, Maki R, Kelsen D, Schwartz G. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. Journal of Clinical Oncology 2005; 23:1875-1884.
25. Krug L, Ng K, Kris M, Miller V, Tong W, Heelan R, Leon L, Leung D, Kelly J, Grant S, Sirotnak F. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clinical Cancer Research 2000; 6:3493-3498.
26. Shah M, Kortmansky J, Motwani M, Drobnjak M, Gonen M, Yi S, Weyerbacher A, Cordon Cardo C, Lefkowitz R, Brenner B, O'Reilly E, Saltz L, Tong W, Kelsen D, Schwartz G. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clinical Cancer Research 2005; 11:3836-3845.
27. Agresti A, Coull B. Approximate is better than exact for interval estimation of binomial proportions. The American Statistician 1998; 52:8.
28. Morris MD. Small-sample confidence limits for parameters under inequality constraints with application to quantal bioassay. Biometrics 1988; 44:1083-1092.
29. O'Quigley J, Paoletti XJM. Non-parametric optimal design in dose finding studies. Biostatistics 2002; 3:51-56.